Literature DB >> 20180596

Homodimerization of the p51 subunit of HIV-1 reverse transcriptase.

Xunhai Zheng1, Geoffrey A Mueller, Matthew J Cuneo, Eugene F Derose, Robert E London.   

Abstract

The dimerization of HIV reverse transcriptase (RT), required to obtain the active form of the enzyme, is influenced by mutations, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide substrates, Mg ions, temperature, and specifically designed dimerization inhibitors. In this study, we have utilized nuclear magnetic resonance (NMR) spectroscopy of the [methyl-(13)C]methionine-labeled enzyme and small-angle X-ray scattering (SAXS) to investigate how several of these factors influence the dimerization behavior of the p51 subunit. The (1)H-(13)C HSQC spectrum of p51 obtained at micromolar concentrations indicates that a significant fraction of the p51 adopts a "p66-like" conformation. SAXS data obtained for p51 samples were used to determine the fractions of monomer and dimer in the sample and to evaluate the conformation of the fingers/thumb subdomain. All of the p51 monomer observed was found to adopt the compact, "p51C" conformation observed for the p51 subunit in the RT heterodimer. The NMR and SAXS data indicate that the p51 homodimer adopts a structure that is similar to the p66/p51 heterodimer, with one p51C subunit and a second p51 subunit in an extended, "p51E" conformation that resembles the p66 subunit of the heterodimer. The fractional dimer concentration and the fingers/thumb orientation are found to depend strongly on the experimental conditions and exhibit a qualitative dependence on nevirapine and ionic strength (KCl) that is similar to the behavior reported for the heterodimer and the p66 homodimer. The L289K mutation interferes with p51 homodimer formation as it does with formation of the heterodimer, despite its location far from the dimer interface. This effect is readily interpreted in terms of a conformational selection model, in which p51(L289K) has a much greater preference for the compact, p51C conformation. A reduced level of dimer formation then results from the reduced ratio of the p51E(L289K) to p51C(L289K) monomers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180596      PMCID: PMC5590755          DOI: 10.1021/bi902116z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

1.  Factors affecting the dimerization of the p66 form of HIV-1 reverse transcriptase.

Authors:  J F Cabodevilla; L Odriozola; E Santiago; J J Martínez-Irujo
Journal:  Eur J Biochem       Date:  2001-03

2.  Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer.

Authors:  J Wang; S J Smerdon; J Jäger; L A Kohlstaedt; P A Rice; J M Friedman; T A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

3.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes.

Authors:  J Ren; R Esnouf; E Garman; D Somers; C Ross; I Kirby; J Keeling; G Darby; Y Jones; D Stuart
Journal:  Nat Struct Biol       Date:  1995-04

4.  Structure/function studies of HIV-1(1) reverse transcriptase: dimerization-defective mutant L289K.

Authors:  R Goel; W A Beard; A Kumar; J R Casas-Finet; M P Strub; S J Stahl; M S Lewis; K Bebenek; S P Becerra; T A Kunkel
Journal:  Biochemistry       Date:  1993-12-07       Impact factor: 3.162

5.  Expression and nitrogen-15 labeling of proteins for proton and nitrogen-15 nuclear magnetic resonance.

Authors:  D C Muchmore; L P McIntosh; C B Russell; D E Anderson; F W Dahlquist
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

6.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

7.  The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.

Authors:  Joeri Auwerx; Joke Van Nieuwenhove; Fátima Rodríguez-Barrios; Sonia de Castro; Sonsoles Velázquez; Francesca Ceccherini-Silberstein; Erik De Clercq; María-José Camarasa; Carlo-Federico Perno; Federico Gago; Jan Balzarini
Journal:  FEBS Lett       Date:  2005-04-25       Impact factor: 4.124

8.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization.

Authors:  M Ghosh; P S Jacques; D W Rodgers; M Ottman; J L Darlix; S F Le Grice
Journal:  Biochemistry       Date:  1996-07-02       Impact factor: 3.162

9.  Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization.

Authors:  Julien Depollier; Marie-Laure Hourdou; Gudrun Aldrian-Herrada; Paul Rothwell; Tobias Restle; Gilles Divita
Journal:  Biochemistry       Date:  2005-02-15       Impact factor: 3.162

10.  Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.

Authors:  Anna Figueiredo; Shannon Zelina; Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

View more
  13 in total

1.  Conformational dependence of 13C shielding and coupling constants for methionine methyl groups.

Authors:  Glenn L Butterfoss; Eugene F DeRose; Scott A Gabel; Lalith Perera; Joseph M Krahn; Geoffrey A Mueller; Xunhai Zheng; Robert E London
Journal:  J Biomol NMR       Date:  2010-08-24       Impact factor: 2.835

2.  Efavirenz binding site in HIV-1 reverse transcriptase monomers.

Authors:  Valerie A Braz; Mary D Barkley; Rebecca A Jockusch; Patrick L Wintrode
Journal:  Biochemistry       Date:  2010-11-19       Impact factor: 3.162

3.  Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Biophys J       Date:  2013-06-18       Impact factor: 4.033

Review 4.  HIV-1 Reverse Transcriptase: A Metamorphic Protein with Three Stable States.

Authors:  Robert E London
Journal:  Structure       Date:  2019-01-10       Impact factor: 5.006

5.  Identification of drivers for the metamorphic transition of HIV-1 reverse transcriptase.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Kyungmin Kim; Lalith Perera; Eugene F DeRose; Robert E London
Journal:  Biochem J       Date:  2017-09-24       Impact factor: 3.857

6.  Fast methionine-based solution structure determination of calcium-calmodulin complexes.

Authors:  Jessica L Gifford; Hiroaki Ishida; Hans J Vogel
Journal:  J Biomol NMR       Date:  2011-03-01       Impact factor: 2.835

7.  Relative domain orientation of the L289K HIV-1 reverse transcriptase monomer.

Authors:  Zhaoyong Xi; Tatiana V Ilina; Michel Guerrero; Lixin Fan; Nicolas Sluis-Cremer; Yun-Xing Wang; Rieko Ishima
Journal:  Protein Sci       Date:  2022-05       Impact factor: 6.725

8.  The p66 immature precursor of HIV-1 reverse transcriptase.

Authors:  Naima G Sharaf; Eric Poliner; Ryan L Slack; Martin T Christen; In-Ja L Byeon; Michael A Parniak; Angela M Gronenborn; Rieko Ishima
Journal:  Proteins       Date:  2014-05-12

9.  Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war.

Authors:  Xunhai Zheng; Lars C Pedersen; Scott A Gabel; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Nucleic Acids Res       Date:  2016-01-14       Impact factor: 16.971

10.  Asymmetric conformational maturation of HIV-1 reverse transcriptase.

Authors:  Xunhai Zheng; Lalith Perera; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Elife       Date:  2015-06-03       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.